Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery

被引:16
|
作者
Colson, P
Ryckwaert, F
Ribstein, J
Mann, C
Dareau, S
机构
[1] Hop Arnaud de Villeneuve, Serv Anesthesie Reanimat B, F-34295 Montpellier, France
[2] Hop Arnaud de Villeneuve, Serv Med Interne G, F-34295 Montpellier, France
关键词
surgery; pheochromocytoma; blood pressure; calcium antagonist;
D O I
10.1111/j.1399-6576.1998.tb05387.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Favourable outcome of phaeochromocytoma surgery requires that paroxysmal hypertension and arrhythmia be controlled, and that hypotension be prevented. Is nicardipine, a calcium channel blocking drug, always adequate ? Methods: Nineteen consecutive patients underwent surgery for phaeochromocytoma. Management was standardised with regards to anaesthesia and antihypertensive treatment. Nicardipine was used as a vasodilator and was given in order to maintain systemic vascular resistance lower than 1600 dyn.s.cm(-5). Results: Hypertension did not occur at any time during surgery in 6/19 patients. Blood pressure rose acutely in 3/19 patients at the time of tracheal intubation or surgical approach to the tumour, and was controlled by increased depth of anaesthesia. Hypertensive episodes occurred in 11/19 patients during tumour manipulation. Nicardipine always succeeded in maintaining low systemic vascular resistance but its dosage varied widely between patients (0.5 to 70 mg), a fact that may be accounted for by the striking intersubject variability of haemodynamic behaviour during surgery. In 7/11 patients, despite nicardipine treatment, sustained increase in blood pressure persisted with increased cardiac index, but low systemic vascular resistance. Following tumour removal, transient serious hypotension (MAP <60 mmHg) occurred in 4 patients, and was corrected by fluid volume expansion. Perioperative incidence of hypertension or hypotension was not related to preoperative clinical status. Conclusion: Adequate management of patients operated upon for phaeochromocytoma requires invasive monitoring, since the mechanisms underlying hypertensive crises are heterogeneous with regards to systemic vascular resistance and not predictable from preoperative data. Nicardipine provides a good control of vasoconstriction during phaeochromocytoma surgery with limited risk of serious hypotension after tumour removal.
引用
收藏
页码:1114 / 1119
页数:6
相关论文
共 50 条
  • [21] Successful Recovery from Severe Fever with Thrombocytopenia Syndrome and Hemophagocytic Lymphohistiocytosis with Standard Treatment and a Calcium Channel Blocker of Nicardipine Hydrochloride
    Yamauchi, Nao
    Hongo, Takashi
    Kawakami, Manri
    Inoguchi, Kyosuke
    Oguni, Syunsuke
    Momoki, Noriya
    Ueno, Akiko
    Ikeda, Fusao
    Fujioka, Shinichi
    Yamamoto, Kazuhide
    INTERNAL MEDICINE, 2023, 62 (09) : 1365 - 1369
  • [22] EFFECTS OF INTRAVENOUS NICARDIPINE, A CALCIUM ENTRY BLOCKER, ON RENAL-FUNCTION DURING ANESTHESIA
    MOMOSE, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 213 - 213
  • [23] Hormonal Crosstalk with Calcium Channel Blocker during Implantation
    Banerjee, Aryamitra
    Padh, Harish
    Nivsarkar, Manish
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2011, 57 (04) : 186 - 189
  • [24] TREATMENT OF REFRACTORY SHOCK IN CALCIUM CHANNEL BLOCKER TOXICITY
    Deveaux, Hillary
    Deleveaux, Spencer
    Qureshi, Abdullah
    CHEST, 2023, 164 (04) : 2177A - 2178A
  • [25] Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning
    Huang, Jessica
    Buckley, Nicholas A.
    Isoardi, Katherine Z.
    Chiew, Angela L.
    Isbister, Geoffrey K.
    Cairns, Rose
    Brown, Jared A.
    Chan, Betty S.
    CLINICAL TOXICOLOGY, 2021, 59 (06) : 464 - 471
  • [26] Clevidipine.: Treatment of hypertension, calcium channel blocker
    Sorbera, LA
    Castañer, J
    DRUGS OF THE FUTURE, 2004, 29 (02) : 105 - 111
  • [27] CALCIUM-CHANNEL BLOCKER FOR TREATMENT OF MALIGNANT HYPERTHERMIA
    IWATSUKI, N
    KOGA, Y
    AMAHA, K
    ANESTHESIA AND ANALGESIA, 1983, 62 (09): : 861 - 862
  • [28] Treatment for calcium channel blocker poisoning: A systematic review
    St-Onge, M.
    Dube, P. -A.
    Goselin, S.
    Guimont, C.
    Godwin, J.
    Archambault, P. M.
    Chauny, J. -M.
    Frenette, A. J.
    Darveau, M.
    Le Sage, N.
    Poitras, J.
    Provencher, J.
    Juurlink, D. N.
    Blais, R.
    CLINICAL TOXICOLOGY, 2014, 52 (09) : 926 - 944
  • [29] Angiotensin II for Treatment of Calcium Channel Blocker Overdose
    Felzer, J. R.
    Hoskote, S. S.
    Chalmers, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [30] CONFIRMATION OF THE INTERACTION BETWEEN CYCLOSPORINE AND THE CALCIUM-CHANNEL BLOCKER NICARDIPINE IN RENAL-TRANSPLANT PATIENTS
    CANTAROVICH, M
    HIESSE, C
    LOCKIEC, F
    CHARPENTIER, B
    FRIES, D
    CLINICAL NEPHROLOGY, 1987, 28 (04) : 190 - 193